Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.30 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.30 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.30 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5169223 | 0.83 | GRIA1 (0.38) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL5168903 | 0.81 | GRIK1 (0.35) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL5190085 | 0.79 | GRIA1 (0.39) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5168343 | 0.79 | GRIA1 (0.37) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5166749 | 0.79 | GRIA1 (0.37) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5168337 | 0.79 | GRIA1 (0.31) | CA12CA9GRIA1GRIA2GRIA3 | |
| SCHEMBL5182464 | 0.78 | PTGS2 (0.38) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5469141 | 0.77 | TLR2 (0.36) | — | |
| SCHEMBL5165979 | 0.77 | GRIA1 (0.34) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5455598 | 0.76 | GRIK1 (0.51) | CA12CA9GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773788-B1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1773788-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS-PHARMA GMBH (AT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010591-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | CA12 4138/4885CA9 2807/4885GRIA1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.